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LETTER TO THE EDITOR
A human plasma derived supplement 
preserves function of human vascular cells 
in absence of fetal bovine serum
C. Castells‑Sala1, J. Martorell1*  and M. Balcells1,2
Abstract 
Current techniques for cell culture routinely use animal‑derived components. Fetal bovine serum (FBS) is the most 
widely applied supplement, but it often displays significant batch‑to‑batch variations and is generally not suitable for 
clinical applications in humans. A robust and xeno‑free alternative to FBS is of high interest for cellular therapies, from 
early in vitro testing to clinical trials in human subjects. In the current work, a highly consistent human plasma derived 
supplement (SCC) has been tested, as a potential substitute of FBS in primary human vascular cells culture. Our results 
show that SCC is able to support proliferation, preserve cellular morphology and potentiate functionality analogously 
to FBS. We conclude that SCC is a viable substitute of FBS for culture and expansion of cells in advanced therapies 
using human vascular cells and fibroblasts.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Dear Editor,
The development of cellular therapies for the treatment 
of malignant and non-malignant diseases has grown 
exponentially over the last decade. Nevertheless, only 
a few products for cell therapy such as Carticel, Azfi-
cel-T and ALLOCORD have been approved for medi-
cal use. The road from bench top to market of human 
grafts, devices and cell therapy products can be long; 
these products usually undergo extensive in vitro testing 
prior to preclinical studies in established animal models 
and final implantation in human subjects. Additionally, 
in  vitro cellular expansion is often necessary to attain 
the required number of cells prior to clinical use. In-
depth cellular characterization is extremely important in 
order to establish the most appropriate environment for 
expansion, analysis and implantation. It is widely known 
that environmental conditions affect cellular phenotype 
and function [1, 2] and hence choosing the right milieu 
is key to a successful therapy. Fetal bovine serum (FBS), 
in particular, which is rich in growth factors (GF) and 
low molecular weight molecules like hormones, and has 
been demonstrated to possess low levels of antibodies, is 
a common supplement due to its widespread availabil-
ity and easy storage [7]. It has been previously reported, 
however, that FBS introduces a great deal of inter-batch 
variability, which means that depending on the FBS batch 
used, cells may respond differently to identical stimuli [7]. 
Since its introduction, cell culture has remained mostly 
unaltered. Current techniques for cell culture routinely 
use animal-derived components. Theoretical risks of 
using human cells cultured with animal-derived reagents 
for transplantation include severe anaphylaxis, presence 
of animal pathogens and immune reactions due to pres-
ence of xenogeneic antigens [1, 3]. Most available cell 
lines have been directly or indirectly exposed to products 
of animal origin during their derivation and/or propaga-
tion in vitro, which limits their clinical application [3, 4].
Good manufacturing practices (GMPs) are essential 
to provide cells with well-defined characteristics that 
are safe for the patient. GMP quality, defined by both 
the European Medicine Agency and the Food and Drug 
Administration, is a requirement for clinical grade cells 
that offer optimal defined quality and safety for cellular 
transplantation [5]. It covers both manufacturing and 
testing of the final product, traceability of raw materials 
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and validated standard operating procedures (SOPs). 
These quality and safety requirements for cell-based ther-
apeutic products prompted the scientific community to 
consider removing xeno-derived components from every 
step of the production of cells; i.e. derivation, passaging, 
expansion and cryopreservation procedures [3, 4].
FBS has been used in cellular transplantation only in 
life-and-death situations. Macchiarini et al. documented 
a case in which a tissue-engineered airway was implanted, 
using a donor with blood type O and where major histo-
compatibility complexes were thoroughly removed using 
exhaustive detergent methods [6]. The safety and quality 
of the transplanted cells may be significantly enhanced 
by replacing FBS and other animal-derived cell culture 
reagents with allogenic human serum (HS) or a defined 
serum-free (SF) or xeno-free (XF) media formulation. 
Human serum has been used to replace FBS in cell cul-
ture with success limited to a few encouraging cases [7]. 
Richards and Ellerström (in 2002 and 2006, respectively) 
derived human embryonic stem cells lines (hESC) using 
culture medium containing human serum. Ellerström 
was able to propagate hESC in HS-containing culture 
medium in an undifferentiated state for over 20 passages. 
Additionally, pooled allogenic HS, platelet-rich plasma 
or human platelet lysate have been reported to support 
equally higher proliferation rates and multilineage dif-
ferentiation capacity of bone marrow mesenchymal stem 
cells and adipose stem cells [1]. Human sera-based sup-
plements have been previously tested in the culture of 
human mesenchymal stem cells as potential substitutes 
for FBS [8]. The current consensus is that human-derived 
serum supplements are a safe alternative to FBS in stem-
cell based therapies. However, in the few successful cases 
published, the serum was pooled individually for each 
patient.
The xeno-free human plasma derived supplement SCC, 
under development at Grifols, is a freeze-dried prepara-
tion obtained from human plasma through cold-ethanol 
industrial fractionation manufactured under good man-
ufacturing practice (GMP) rules. Fractionation plasma 
pools contain donations from over 1000 different healthy 
donors, ensuring that SCC biological properties are con-
sistent from lot to lot. Overall, SCC’s advantage is that, 
despite being from human origin, it possesses a well-
defined composition, no batch to batch variability and no 
xenogeneic traces, which are the main concerns raised by 
the FDA to approve sera for stem-cell based therapies.
Here, we explore and characterize the role played by 
a human plasma derived xeno free supplement (SCC) 
as an alternative to FBS in the regulation of cell growth, 
morphology, phenotype and activity in two-dimensional 
cellular cultures. Our results suggest that SCC effec-
tively guarantees cellular proliferation, morphology, 
phenotype, and activity in three highly relevant cell types 
that can be used to recapitulate the arterial structure in 
research in cardiovascular diseases: human umbilical 
vein endothelial cells (hUVEC), human aortic smooth 




Proliferation capacity of human umbilical vein endothe-
lial cells (hUVEC), human aortic smooth muscle cells 
(hAoSMC), and normal human dermal fibroblasts 
(NHDF) was analyzed in medium supplemented with 
SCC or FBS at different concentrations (5 and 10%). Cells 
were trypsinized and cultured in a 48 well-plate at the 
cell density recommended by the supplier (hUVEC—
6500 cells/cm2; hAoSMC—7500  cells/cm2 and NHDF—
4000 cells/cm2) and exposed to the corresponding serum 
(FBS or SCC) for at least two doubling times prior to any 
experimentation in order to assure proper acclimation to 
the serum.
Ki-67, a nuclear transcription factor crucial for cel-
lular proliferation, was stained in order to estimate cel-
lular proliferation (Fig. 1). We measured the percentage 
of nuclei that stained positively for Ki-67, showing that 
hUVEC, hNDF and hAoSMC are capable to proliferate in 
both supplemented media either at 5 and 10% FBS and 
SCC.
Viability assay was conducted using a tetrazolium 
salt assay, specifically MTS ((3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium)) during the first 6  days of culture. 
Results summarized in Fig.  2 show the daily MTS val-
ues normalized to the MTS value at day 1 for cells cul-
tured as recommended by the provider (5% FBS + GF). 
Growth factors (GF) deprivation caused a significant 
decrease in MTS signal in hUVEC. Only hAoSMC cul-
ture with 5% SCC without GF showed lower MTS signal 
than the other conditions. In contrast, the absence of GF 
in NHDF cultures did not cause any significant differ-
ence in cell proliferation. Interestingly, in the presence of 
growth factors, no significant differences were observed 
between cells cultured with SCC supplemented media 
and those cultured with FBS supplemented media in any 
cell type. All cells studied proliferated at similar rates 
regardless of the supplement applied. NHDF growth 
kinetics were almost independent of sera type and 
concentration.
Cellular structure
Cellular structure is a determinant of the cellular phe-
notype. We tested whether SCC modified cellular 
morphology, comparing it to that of cells cultured in 
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Fig. 1 Proliferation analysis by immunofluorescence staining of Ki‑67 after 36 h of culture. Ki67 expression (green) can be observed in the nuclei 
of every cell type in FBS‑ and SCC‑supplemented media. Cells were counterstained for actin filaments using phalloidin‑rhodamine. The number of 
Ki67‑positive nuclei was divided by the number of total nuclei to give an estimate of cells proliferating. Results are presented as mean ± standard 
deviation obtained from three independent values per group. No significant differences were observed between groups after nonparametric 
Kruskal–Wallis test, followed by a Scheffé posthoc analysis
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FBS-supplemented medium. We also compared our cul-
tures with in vivo samples from the aorta of a Yorkshire 
pig. Figure 3 shows the morphological structure of cells 
supplemented with different levels of FBS or SCC and the 
comparison with the phenotype observed in a porcine 
aorta. The adjacent graphics show the cellular orientation 
dispersion in the in vivo example compared with the dis-
persion of in vitro cell cultures.
hUVEC cultured in all conditions showed homogene-
ous expression of platelet/endothelial cell adhesion mol-
ecule 1 (PECAM-1 or CD31) in their membranes and 
especially at the intercellular junctions. Endothelial cells 
cultured in FBS and SCC were disposed in a classic cob-
blestone display. Intercellular connectivity through CD31 
bridges was maintained in all cases. In the porcine model, 
endothelial cells presented a paved structure aligned to 
Fig. 2 Viability assay of different cell types growing in media supplemented with different concentrations of FBS and SCC in presence or absence 
of GF after 6 days of culture. The first column corresponds to 5% of FBS or SCC and the second to 10% of FBS or SCC. Results are normalized to the 
MTS value at day 1 for cells supplemented with growth factors and FBS at the concentration recommended by the provider. Results are presented 
as mean ± standard deviation obtained from three independent values per group. One‑way analysis of variance was performed comparing means 
with Tukey’s post‑test. All assays comparisons were made by correlation and linear regression analysis. Differences were considered significant if 
p < 0.05
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flow [9]. The in vivo orientation analysis shows two peaks, 
coherent with a rectangular shape. Similarly, endothelial 
cells cultured in  vitro with FBS or SCC present a simi-
lar distribution. Indeed, the mean dispersion of orienta-
tions was around 10% in all cases. hAoSMC cultured in 
all conditions displayed uniform expression of α-smooth 
muscle actin. Actin filaments were aligned even when 
multilayers were formed. In the porcine aorta, an exten-
sive multilayer of smooth muscle cells can be observed, 
with cells clearly aligned and elongated perpendicular 
to flow. The in vivo orientation analysis shows a narrow 
peak, coherent with cells with an elongated shape and 
clear alignment. Smooth muscle cells cultured in  vitro 
with FBS or SCC present an analogous morphology, 
and the mean dispersion of orientations was below 4% 
in all cases. No differences in collagen I expression were 
observed between NHDF cultured in FBS- or SCC-sup-
plemented medium. Collagen I fibers bundled to ensure 
cohesion and continuity of the fibroblast multilayer, both 
in the cultures and the naïve aorta. Of note, dermal and 
adventitial have many phenotypical differences. However, 
they both create supportive tissue by building a protein 
network, using collagen fibers and fibronectin amongst 
other molecules. As fibroblasts do not align but create 
a support tridimensional matrix, their spatial distribu-
tion is much sparser. Our orientation analysis revealed a 
broad plateau, both in vitro and in vivo, with mean dis-
persion ranging between 15 and 35%.
In conclusion, cells incubated with FBS- and SCC-
supplemented media exhibited the same morphological 
Fig. 3 Analysis of cell structure by immunofluorescence. In terms of cell structure, CD31 was stained for endothelial cells, actin α smooth muscle 
for smooth muscle cells and collagen I for fibroblasts. Specific proteins are stained in green and nuclei in blue. Cellular orientation distribution was 
measured using Fiji’s plugin “Orientation J Distribution”. The Gaussian distribution of cellular orientations was centered on 0 and all values were 
divided by each case’s maximum value in order to get a normalized orientation value between 0 and 1. The mean dispersion percentage was calcu‑
lated as the angle range that contained 80% of the orientations, divided by 180°
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endogenous markers than in  vivo and a similar spatial 
distribution.
Cellular activity
A marker of cellular activity relevant to each studied 
cell type was chosen and examined at different FBS and 
SCC concentrations. Interestingly, the cellular reactivity 
of studied cells was significantly different between the 
proposed serum and FBS, the standard used in research. 
Inflammatory response of hUVEC was measured by 
western blot after addition of tumor necrosis factor 
alpha (TNF-α) to stimulate intercellular adhesion mol-
ecule 1 (ICAM–1) expression (see Fig. 4a). Pro-coagulant 
response to injury of smooth muscle cells was evaluated 
by quantitative immunofluorescence of tissue factor 
(TF) expression (see Fig. 4b). NHDF extracellular matrix 
synthesis was detected measuring fibronectin expres-
sion using Western Blot (see Fig. 4c). In vivo, endothelial 
cells are responsible to form the vascular endothelium, 
a semipermeable barrier responsible for regulating the 
exchange between blood and peripheral tissues. Addi-
tion of the inflammatory cytokine TNF-α to the culture 
medium provoked a significant increase of ICAM-1 
expression in FBS- and SCC-supplemented media in 
all cases (data obtained without TNF-α is not shown). 
Results of samples treated with TNF-α are expressed as 
ICAM-1 expression divided by tubulin expression and 
normalized to the results obtained in cells cultured in 
Fig. 4 Cell activity analysis. Comparison of protein expression between cells supplemented with FBS and SCC at different levels. a ICAM‑1 expres‑
sion was analyzed by Western Blotting after the addition of TNF‑α. b Tissue factor expression in injured human aortic smooth muscle cells was 
evaluated by immunofluorescence. The fluorescence intensity (green) was measured at the edge of the injury and divided by the number of cells. c 
Fibronectin expression in human normal dermal fibroblasts was analyzed by Western Blotting. All results are normalized to the value of FBS 5% and 
presented as mean ± standard error of mean as obtained of three independent values per group. Nonparametric Kruskal–Wallis test, followed by a 
Scheffé posthoc analysis was performed, and differences were considered significant if p < 0.05
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medium supplemented with 5% FBS. ICAM-1 expression 
after TNF–α stimulation was up to two-fold higher in 
cells supplemented with SCC compared to cells supple-
mented with FBS (p < 0.05) (Fig. 4a). One may infer that 
SCC enhances ICAM-1 expression in hUVEC. This result 
is very relevant in case of transplantation of endothelial 
cells in novel arterial replacements [10]. The expression 
of ICAM-1 could enhance endothelial progenitor cells 
recruitment and angiogenesis, favoring revasculariza-
tion of the implant and hence increasing the chance of 
success.
Exposure of tissue factor (TF) present in smooth 
muscle cells to the blood torrent triggers the coagula-
tion cascade. Overexposure of TF serves as a key pre-
cipitant of injury-related local clot formation and can 
lead to thrombosis, a potentially lethal event. In animal 
models of balloon arterial injury, TF is rapidly induced 
in smooth muscle cells. In our experiments, we injured 
hAoSMC in  vitro and analyzed TF after injury. TF was 
overexpressed in cells surrounding the injury area, 
and such cells migrated towards the denuded, cell-free 
regions. Results are expressed as TF expression in injured 
cells relative to TF expression in non-injured cells. The 
results presented in Fig. 4b show that TF expression was 
not different between sera concentrations nor origin. In 
all cases, injured hAoSMC increased their TF expres-
sion between 30 and 50% when compared to their intact 
neighbors. We observed that TF expression bump after 
injury was marginally higher in hAoSMC cultured with 
FBS than in SCC, but not significantly. SCC did not affect 
this two-edged sword defense mechanism in hAoSMC.
In fibroblasts, activity is given by the ability to build 
extracellular matrix (ECM). Fibronectin, which binds to 
integrins, collagen, fibrin and heparin sulfate proteogly-
cans, plays a major role in cell adhesion, growth, migra-
tion and differentiation. Figure 4c shows that fibronectin 
was slightly overexpressed in fibroblasts cultured with 
SCC medium, but only significantly (p < 0.05) when com-
paring 10% SCC to 10% FBS. These results indicate that 
SCC promotes extracellular matrix formation by fibro-
blasts as powerfully as FBS at 5% serum concentration 
and better at 10%. These differences may be due to dif-
ferent concentration of low molecular weight molecules. 
These molecules could alter ECM protein deposition in 
fibroblasts and depleting SCC from them could be an 
inherent advantage to the product.
Conclusions
We have shown how SCC, a human plasma derived sup-
plement SCC is able to sustain growth, morphology and 
function of human endothelial cells, smooth muscle cells 
and fibroblasts, equally or even better than fetal bovine 
serum. As a xeno-free product, GMP-compliant and 
ensuring lot to lot consistency, the introduction of SCC 
at early stages of development of advanced cell therapies 
may ease fulfillment of safety and efficacy requirements 
prior to clinical studies.
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